Benzinga
Benzinga
Benzinga
samedi, septembre 26

Halozyme Therapeutics Inc

HALONASDAQ
Trade with Public
Trade with Public
$113.90
-1.32-1.15%
À la clôture: Sep 25, 5:00 PM EST
$114.18
0.280.25%
Après les heures: 4:02 PM EST
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentActionnariatComparerOptionsRapport sur les stocks

Halozyme Therapeutics Financials

Halozyme Therapeutics (HALO) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Halozyme Therapeutics Q2 Adj. EPS $2.28 Beats $1.84 Estimate, Sales $480.999M Beat $407.493M Estimate

Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $2.28 per share which beat the analyst consensus estimate of $1.84 by 23.91 percent. This is a 48.05 percent increase over earnings of $1.54 per share
Benzinga Newsdesk

PRO
Halozyme Therapeutics Raises FY2026 Adj EPS Guidance from $7.75-$8.25 to $8.65-$9.00 vs $8.14 Est; Raises FY2026 Sales Guidance from $1.710B-$1.810B to $1.835B-$1.910B vs $1.773B Est

Halozyme Therapeutics (NASDAQ:HALO) raises FY2026 Adj EPS guidance from $7.75-$8.25 to $8.65-$9.00 vs $8.14 analyst estimate. Raises FY2026 sales outlook from $1.710 billion-$1.810 billion to $1.835 billion-$1.910
Benzinga Newsdesk

PRO
Halozyme Therapeutics Affirms FY2026 Adj EPS Guidance of $7.75-$8.25 vs $8.09 Est; Affirms FY2026 Sales Guidance of $1.710B-$1.810B vs $1.760B Est

Halozyme Therapeutics (NASDAQ:HALO) affirms FY2026 Adj EPS guidance from $7.75-$8.25 to $7.75-$8.25 vs $8.09 analyst estimate. Affirms FY2026 sales outlook from $1.710 billion-$1.810 billion to $1.710 billion-$1.810
Benzinga Newsdesk

PRO
Halozyme Therapeutics Q1 Adj. EPS $1.60 Beats $1.53 Estimate, Sales $376.708M Beat $359.053M Estimate

Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $1.60 per share which beat the analyst consensus estimate of $1.53 by 4.58 percent. This is a 44.14 percent increase over earnings of $1.11 per share
Benzinga Newsdesk

Earnings Scheduled For May 11, 2026

Benzinga Insights

Halozyme Therapeutics Earnings Report: Q4 Overview

Benzinga Insights

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved